# US 2003/0077571 A1 · Experimental model and method for evaluation of therapeutic agents against asthenopia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0077571 A1
- Document ID: US20030077571A1
- Status: Published application
- Kind: A1
- Application number: 10/092,210
- Filed: 2002-03-06
- Published: 2003-04-24
- Earliest claimed: 2001-04-26
- Inventors: Iwao Katsuyama
- Web page: https://patentgrep.com/patent/US20030077571A1

## CPC

- G01N 33/5085: {of invertebrates}
- A61P 27/02: Ophthalmic agents
- G01N 33/5088: {of vertebrates}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention provides a experimental model and method for evaluating and screening drugs or quasi-drugs against asthenopia, including accommodative asthenopia, by preparing a ciliary muscle sample enucleated from a non-human animal, inducing contraction by one or more of contraction stimulants, measuring the contraction rate of the ciliary muscle, treating it with a test formulation and measuring the contraction rate of the ciliary muscle after such treatment.

## Claims

### Claim 1

An experimental model for evaluating the effect of a medicine against asthenopia, wherein said asthenopia is caused by inducing repeated contraction in vitro of ciliary muscle from a non-human animal until said ciliary muscle shows a substantially stable decrease in the tension of muscular contraction.

### Claim 2 (depends on 1)

The experimental model of claim 1, wherein said asthenopia is accommodative asthenopia.

### Claim 3 (depends on 1)

The experimental model of claim 1, wherein the ciliary muscle has been derived from a non-human mammal or fowl.

### Claim 4 (depends on 2)

The experimental model of claim 2, wherein the ciliary muscle has been derived from a non-human mammal or fowl.

### Claim 5 (depends on 3)

The experimental model of claim 3, wherein the ciliary muscle has been enucleated from a non-human mammal.

### Claim 6 (depends on 4)

The experimental model of claim 4, wherein the ciliary muscle has been enucleated from a non-human mammal.

### Claim 7 (depends on 1)

The experimental model of claim 1, wherein the ciliary muscle is contracted a plurality of times by the use of smooth muscle contraction-inducing means.

### Claim 8 (depends on 7)

The experimental model of claim 7, wherein the smooth muscle contraction-inducing means comprise a chemical stimulant.

### Claim 9 (depends on 8)

The experimental model of claim 8, wherein the chemical stimulant is selected from the group consisting of acetylcholine, serotonin, histamine, muscarine, nicotine and endothelin.

### Claim 10 (depends on 7)

The experimental model of claim 7, wherein the smooth muscle contraction-inducting means comprises an electrical stimulant.

### Claim 11 (depends on 1)

The experimental model of claim 1, wherein the contraction of ciliary muscle is repeated at least three times to give a substantially stable decrease in the tension of muscular contraction.

### Claim 12 (depends on 1)

The experimental model of claim 1, wherein said ciliary muscle shows a decrease of 50±30% in the tension of muscular contraction.

### Claim 13 (depends on 1)

The experimental model of claim 1, wherein said ciliary muscle shows a decrease of 50±20% in the tension of muscular contraction.

### Claim 14 (depends on 1)

The experimental model claim 1, wherein said ciliary muscle shows a decrease of 50±10% in the tension of muscular contraction.

### Claim 15

A method of preparing an in vitro experimental model for evaluating the effect of a medicine against asthenopia, which comprises the step of inducing repeated contractions of ciliary muscle derived from a non-human animal until said ciliary muscle shows a substantially stable decrease in the tension of muscular contraction.

### Claim 16 (depends on 1)

A method for evaluating a medicine against asthenopia, comprising the steps of contacting the ciliary muscle from a non-human animal in the experimental model of claim 1 with said medicine, and measuring the effect of said medicine on the contraction of said ciliary muscle.

### Claim 17 (depends on 16)

The method of claim 16, wherein the effect of the medicine is evaluated by comparing the decrease in tension of muscular contraction before and after contacting with the medicine.

### Claim 18 (depends on 16)

The method claimed of claim 16, carried out with use of a Magnus apparatus.
